Articles tagged with Prostate Cancer
A new genomic classifier score predicts aggressive prostate cancer, potentially changing treatment guidelines. The model integrates gene expression biomarker risk scores into existing risk groups, increasing accuracy and confidence in treatment recommendations.
A single PSA test increased detection of low-risk prostate cancer, but made no significant difference in prostate cancer deaths after 10 years. This study suggests that current policy against prostate cancer screening may be justified, as potential benefits are outweighed by harms from overdetection and overtreatment.
A recent trial found that a one-off PSA test does not save lives in asymptomatic men, highlighting the need for more accurate ways to diagnose aggressive prostate cancers. The study of over 400,000 men aged 50-69 showed no significant difference in mortality rates between those who were screened and those who were not.
A novel nuclear medicine imaging agent targeting copper accumulation in tumors detects prostate cancer recurrence early in patients with biochemical relapse. The new imaging agent, copper-64 chloride (64CuCl2), has a higher detection rate than fluorine-18-choline-PET/CT in patients with low levels of PSA (<1 ng/ml).
A phase 3 clinical trial showed apalutamide treatment significantly delayed metastasis development in men with prostate cancer resistant to standard therapy. The treatment also improved survival and reduced disease progression symptoms.
A recent study revealed that patients with inherited DNA repair mutations in metastatic prostate cancer can derive similar benefits from treatment with standard therapies as other patients. Ongoing research explores the potential potency of targeted therapy with PARP inhibitors, which may offer additional therapeutic options for these ...
A recent study found that nearly half of all prostate cancer randomized clinical trials use lab results that disproportionately exclude black patients. The study, published in JAMA Oncology, highlights the need for researchers to adjust entry criteria to prevent racial biases.
Researchers have developed a new method to differentiate cancerous tissue from healthy tissue in prostate cancer patients using PSMA PET/CT scans. The study found that a cutoff value of SUV max = 3.15 can accurately diagnose prostate cancer with high sensitivity and specificity.
PSMA PET/CT detects prostate cancer recurrence earlier than current imaging modalities, enabling more effective salvage radiotherapy. Nearly half of patients with biochemical recurrence show positive results, with lesions often found in bone and perirectal lymph nodes.
A large retrospective study found that obese men and those with metabolic syndrome had a higher risk of biochemical recurrence after radical prostatectomy. Patients with obesity had a 32% higher chance of recurrence compared to those with normal weight, while those with metabolic syndrome had over four-fold increased risk.
Researchers confirmed a mechanistic link between HSD17B4 and treatment-resistant prostate cancer. The study found that men lacking a specific isoform of the gene are more susceptible to aggressive prostate cancer.
A new genetic tool predicts the age of onset for aggressive prostate cancer, guiding decisions on PSA screening. The polygenic hazard score is a highly significant predictor of age at diagnosis, estimating individual genetic risk.
A new study found that a Mediterranean diet rich in fish, boiled potatoes, fruits, vegetables, legumes, and olive oil was associated with a lower risk of aggressive prostate cancer. The diet showed a protective effect on more aggressive tumors, but other dietary patterns had little to no correlation.
A new genetic risk model predicts age of onset for aggressive prostate cancer, guiding screening decisions. Men with high scores are at almost three-fold greater risk of developing aggressive disease.
Researchers at Hokkaido University have identified a cellular protein called STAP-2 that stabilizes the EGFR signaling pathway, leading to increased cell proliferation and tumor formation in prostate cancer. Suppressing STAP-2 with inhibitors could potentially treat Gefitinib-resistant prostate cancers.
A study published in Oncotarget identifies a key step in the modification of Snail1, which can alter its structure and function to promote prostate cancer cell migration. The researchers found that preventing this modification can abolish the migratory and invasive properties of human prostate cancer cells.
A five-year, nearly $12 million study will compare the effectiveness of two radiation treatments for prostate cancer, proton therapy and intensity-modulated radiation therapy (IMRT). The study aims to determine if proton therapy has fewer side effects compared to IMRT.
An international panel of experts has developed a comprehensive set of recommendations for genetic counseling and testing in men with high-risk prostate cancer. The guidelines aim to inform screening, treatment planning, and personalized care, taking into account the rapidly evolving field of practice.
A new study found that a shorter course of radiation therapy using higher doses over fewer days may provide a better outcome for men with intermediate-risk prostate cancer. The study analyzed data from over 5,000 men and showed a significant 13% reduction in the risk of recurrence with hypofractionated radiation therapy (HRT) compared ...
A study by Australian researchers demonstrates that PSMA PET scans can identify prostate cancer patients who would benefit from salvage radiation treatment. The study shows an overall treatment response of 72 percent, with men having negative or fossa-confined PSMA having the highest treatment response to SRT.
A new method using single-cell genomics can help identify potentially lethal prostate tumors before surgery, improving risk assessment and treatment decisions. The approach analyzes genomic patterns in biopsy cores, assigning a score based on clonality and genetic aberrations.
A new study at the University of Michigan identifies a pathway that links efferocytosis, the process of removing dead cells, to tumor growth in metastatic prostate cancer. The researchers found that a pro-inflammatory protein called CXCL5 accelerates tumor growth and sheds light on novel effective cancer therapies.
The Prostate Health Index test influences physician decisions to perform biopsies, with only 36% of men receiving biopsies when phi testing was included in the assessment compared to 60% before its availability. The study also found a reduction in low-grade prostate cancers detected.
Researchers detected TMPRSS2-ERG fusions in 45% of analyzed prostate cancers, with those retaining interstitial genes showing lower risk of progression. The study suggests that identifying the formation mechanism of gene fusions could help stratify patients into more well-defined risk groups.
A recent study found that dietary isoflavone intake was associated with an elevated risk of advanced prostate cancer, but not non-advanced cases. Isoflavones are a type of phytoestrogen found in soybeans and other plants.
A study published in Annals of Oncology has identified genetic markers that may predict resistance to a specific therapy used for treating advanced prostate cancer. The researchers found that understanding the genetic markers of tumors can help healthcare providers match a therapy that is likely to succeed on the first try.
A new Northwestern Medicine study shows proton therapy outperforms intensity-modulated radiation therapy (IMRT) in five-year overall survival rates, with a 93.25% rate for proton patients compared to 88.43% for IMRT patients. Proton therapy also reduces complications and secondary malignancies, particularly for younger patients.
A recent study by UNC Lineberger Comprehensive Cancer Center researchers found that more than half of men with prostate cancer prefer preserving sexual function, but this preference was not strongly linked to the choice of treatment strategy. Active surveillance is widely recognized as the best option for preserving sexual function, ye...
A new gene expression biomarker has been developed to diagnose prostate cancer type and aggressiveness, enabling clinicians to tailor treatment plans. The study found the diagnostic test to be more effective than standard clinical tests in predicting aggressive disease.
Researchers found that nerves stimulate the formation of new blood vessels that promote tumor growth in prostate cancer. They discovered an "angio-metabolic switch" triggered by norepinephrine binding to endothelial cells, which changes how cells metabolize glucose, favoring glycolysis.
Researchers discovered a testosterone-related genetic variant that can predict individual patient responses to specific prostate cancer therapies. The studies suggest that men with this variant would benefit from personalized treatment plans targeting hormonal pathways.
Androgen receptor targeted imaging is emerging as a potential modality for early, rapid, and efficient diagnosis of prostate cancer. Current medical imaging reviews discuss traditional diagnostic approaches and summarize current imaging approaches using PSMA, BN, and AR targeted imaging.
A new study found that surgical cancer centers in England are investing heavily in unproven technologies to stay competitive, despite a lack of evidence on their effectiveness. This trend has led to the closure of several centers, with patients often traveling to alternative facilities offering robotic surgery.
The University of Texas at San Antonio has received a $354,617 grant to support the development of a novel microscope for detecting prostate cancer through urine samples. This noninvasive approach aims to improve accuracy compared to current clinical practices.
A groundbreaking collaboration has been awarded $2.5 million to explore an innovative new treatment path for breast and prostate cancer. The project aims to 'reprogram' hormone receptors, potentially transforming the lives of those affected by these cancers.
The STAMPEDE trial presents late-breaking results from two new treatments for patients with high risk prostate cancer. Patients starting long-term hormone therapy may benefit equally from docetaxel and abiraterone acetate plus prednisolone, with both treatments providing a survival advantage over standard care alone.
Researchers have developed a new approach to precisely identify and localize prostate cancer tumors while protecting healthy tissue. The double targeting ligand RPS-027 binds to both PSMA and albumin, reducing kidney uptake and increasing tumor-to-tissue ratios for improved therapeutic profile.
Researchers found that anti-hormone therapy can activate DNA repair enzyme PARP, causing cancer cells to become more aggressive. Combining PARP inhibitors with anti-hormone therapy treatment may help reduce prostate cancer recurrence and increase survival rates.
Guidelines recommending against routine PSA-based screening may be revised due to compatible evidence showing screening reduces prostate cancer mortality. The benefits of screening outweigh potential harms of overdiagnosis and overtreatment, but how to implement screening is still a question.
A new imaging technique has been developed to uncover oxygen levels in prostate tumours, potentially leading to a non-invasive way to determine which tumours are more difficult to treat. The technique uses light and sound to image the strength of blood vessels in tumours, helping doctors identify patients with harder-to-treat cancers.
Researchers at The Wistar Institute have developed a gene-based delivery system that instructs the body to generate therapeutic antibodies against cancer cells. This technology has shown promising results in treating prostate cancer by binding to cancer cells and recruiting immune cells, resulting in tumor shrinkage and improved survival.
Researchers at Mayo Clinic have identified a link between SPOP gene mutations and treatment resistance in prostate cancer. The discovery suggests ways to improve therapy by using these mutations as biomarkers. This breakthrough could lead to more effective treatments for this common and deadly form of cancer.
Researchers at Johns Hopkins Medicine discovered a biochemical process that gives prostate cancer cells the ability to change shape and invade other tissues. The study found that a gene called AIM1 is deleted in approximately 20-30% of prostate cancers confined to the gland and 40% of metastatic prostate cancers.
Researchers mapped an acquired mutation altering DNA make-up in 50% of patient tumor samples, identifying a new target for therapy. The discovery highlights the power of mutations to influence epigenetics in cancer cells.
A systematic review and meta-analysis found that both bisphosphonates and denosumab improve bone mineral density in men with nonmetastatic prostate cancer receiving androgen deprivation therapy. Further trials are needed to confirm fracture reduction outcomes.
A novel PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), demonstrates potential for imaging prostate cancer. The tracer shows elevated tumor-to-background ratios and high-contrast images in human cases, suggesting its viability as a replacement for existing tracers.
A 20-year study found that surgery for early-stage prostate cancer did not prolong life and often caused serious complications. Most men with early prostate cancer are more likely to survive with limited or no treatment.
Men who are tall and obese have an increased risk of high grade prostate cancer and death from prostate cancer, according to a study published in BMC Medicine. The research found that height is not associated with overall prostate cancer risk but increases the risk of high grade disease and death by 21% and 17% respectively.
Elena Castro, a Spanish researcher, is awarded the Prostate Cancer Foundation's Young Investigator Award for her project on DNA damage repair genes and their impact on advanced prostate cancer progression. The award supports her work to develop therapeutic strategies for patients with genetic defects.
Research found that genes responsible for differential RNA splicing contribute to tumor aggressiveness and drug resistance in African American men with prostate cancer. The study suggests these genetic variations lead to the production of protein isoforms that make tumors more aggressive, while also causing drug resistance.
A study published in Cell Chemical Biology highlights the need for new treatment approaches for treatment-resistant prostate cancer. Researchers found that effective steroidal anti-androgens share common metabolic activities, suggesting a potential strategy to improve efficacy.
A new three-in-one blood test developed by researchers at the Institute of Cancer Research can pick out men with advanced prostate cancer who are likely to benefit from treatment with PARP inhibitors. The test detects early signs of resistance and monitors cancer's evolution over time, allowing for timely adjustments to treatment.
Researchers demonstrate preclinically that dual-labeled PSMA-inhibitors improve preoperative staging and intra-operative guidance for metastatic prostate cancer patients. This combined approach results in more accurate detection of PSMA-positive tumor lesions, enhancing patient outcomes.
A new imaging test, Ga-68 PSMA PET/CT, has been shown to detect cancer that conventional imaging missed, changing treatment plans for 51% of patients. The test also improved management for patients with recurrent disease, with 69% receiving radiation therapy and 64% undergoing surgery.
Researchers at H. Lee Moffitt Cancer Center identify novel inhibitor (R)-9bMS that targets epigenetic modification of the androgen receptor gene, blocking growth in resistant prostate cancer cells. The discovery offers a new therapeutic option for castration-resistant prostate cancer patients who do not respond to enzalutamide.
Researchers demonstrated the efficacy of targeted photodynamic therapy (tPDT) to treat prostate cancer before and during surgery, using a PSMA-targeting agent coupled with photosensitizers. The technique optimizes prostate cancer care by allowing visualization of tumors prior to surgery and providing real-time guidance to surgeons.
The EV-FPS test correctly identifies men with aggressive prostate cancer 40% more accurately than current PSA tests. It has the potential to eliminate up to 600-thousand unnecessary biopsies and reduce hospitalizations annually in North America.
Researchers at the University of Texas at Austin identified several plant-based compounds that can prevent or slow down prostate cancer growth. The study found that combining these compounds, such as ursolic acid and curcumin, with glutamine can block the nutrient uptake needed by prostate cancer cells.
A study found that black men are more concerned about the impact of treatment on their daily lives, recovery time, and cost, while white men prioritize quality of life and cancer cure. These differences in perceptions may contribute to racial disparities in prostate cancer treatment.
Adding abiraterone acetate to standard hormonal therapy reduces the chance of death by 38% and doubles the median time until cancer worsens. Cancer growth is delayed by 18 months, but severe side effects like high blood pressure and liver enzyme abnormalities are more common with abiraterone.